Annual report pursuant to Section 13 and 15(d)

CONCENTRATIONS

v3.21.1
CONCENTRATIONS
12 Months Ended
Dec. 31, 2020
CONCENTRATIONS  
17. CONCENTRATIONS

17. CONCENTRATIONS

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents and accounts receivable. At December 31, 2020, three customers accounted for approximately 92% of the Company’s consolidated accounts receivable. At December 31, 2019, two customers accounted for 89% of the Company’s total accounts receivable.

 

For the year ended December 31, 2020, three customers represented an aggregate of 82% of the Company’s consolidated revenues. For the year ended December 31, 2019, three customers totaled 70% of the Company’s consolidated revenues.

 

The Company purchases substantially all of its raw material plasma from Grifols. For the year ended December 31, 2020, plasma purchases from Grifols were approximately $25.0 million, or 68% of the Company’s total inventory purchases. For the year ended December 31, 2019, plasma purchases from Grifols totaled approximately $28.6 million, representing approximately 82% of the Company’s total inventory purchases.